Patent classifications
A23V2250/264
Edible edible composition with low caffeine
An energy composition includes a methylated xanthine, a choline derivative, and at least one flavorant in a sufficient amount to render the energy composition palatable. The energy composition may also include vitamins, amino acids, enzymes, preservatives, and the like.
Edible edible composition with low caffeine
An energy composition includes a methylated xanthine, a choline derivative, and at least one flavorant in a sufficient amount to render the energy composition palatable. The energy composition may also include vitamins, amino acids, enzymes, preservatives, and the like.
Whey protein based liquid nutritional composition
Whey protein based liquid nutritional compositions are provided. The liquid nutritional compositions include at least 7% by weight protein and all of the protein is provided by a whey protein hydrolysate and an intact whey protein. The liquid nutritional compositions have a neutral pH, a low viscosity, and are shelf stable.
Whey protein based liquid nutritional composition
Whey protein based liquid nutritional compositions are provided. The liquid nutritional compositions include at least 7% by weight protein and all of the protein is provided by a whey protein hydrolysate and an intact whey protein. The liquid nutritional compositions have a neutral pH, a low viscosity, and are shelf stable.
A COOLING PREPARATION
Suggested is a cooling preparation comprising phenylalkenals and homovanillic acid esters.
A COOLING PREPARATION
Suggested is a cooling preparation comprising phenylalkenals and homovanillic acid esters.
ENCAPSULATED SWEETENER GRANULES AND METHODS OF PREPARATION THEREOF
A method for forming encapsulated sweetener granules (ESGs) may include heating a first mixture to form a molten mixture, the first mixture includes one or more polyols and one or more hydrocolloids; cooling the molten mixture to a first temperature to form a cooled molten mixture; adding one or more high-intensity sweeteners to the cooled molten mixture to form a second mixture; cooling the second mixture to a second temperature to form one or more sheets, the second temperature being different from the first temperature; and fragmenting the one or more sheets to form a plurality of encapsulated sweetener granules. The first temperature may be between about 120° C. and about 200° C. The second temperature may be below a glass transition temperature (T.sub.g) of the one or more polyols and the one or more hydrocolloids. For example, the second temperature may be between about 65° C. and about 200° C.
ENCAPSULATED SWEETENER GRANULES AND METHODS OF PREPARATION THEREOF
A method for forming encapsulated sweetener granules (ESGs) may include heating a first mixture to form a molten mixture, the first mixture includes one or more polyols and one or more hydrocolloids; cooling the molten mixture to a first temperature to form a cooled molten mixture; adding one or more high-intensity sweeteners to the cooled molten mixture to form a second mixture; cooling the second mixture to a second temperature to form one or more sheets, the second temperature being different from the first temperature; and fragmenting the one or more sheets to form a plurality of encapsulated sweetener granules. The first temperature may be between about 120° C. and about 200° C. The second temperature may be below a glass transition temperature (T.sub.g) of the one or more polyols and the one or more hydrocolloids. For example, the second temperature may be between about 65° C. and about 200° C.
Cytochrome P450 Enzyme Complexes And Methods Of Treatment Using The Same
The present invention provides methods and compositions for balancing electron reduction potentials of formulations in a manner that reduces susceptibility to changes from xenobiotics. The present invention also provides novel compositions of matter based on structuring from a mobile nucleotide integral to its architecture.
Cytochrome P450 Enzyme Complexes And Methods Of Treatment Using The Same
The present invention provides methods and compositions for balancing electron reduction potentials of formulations in a manner that reduces susceptibility to changes from xenobiotics. The present invention also provides novel compositions of matter based on structuring from a mobile nucleotide integral to its architecture.